Christian Lhotka

Learn More
BACKGROUND Metal-on-metal total hip prostheses will produce a certain amount of wear debris. This results in increased whole-blood metal levels, which may cause adverse effects. It is not known to what extent the problem has been overcome by advances in alloy technology. METHODS In 259 patients who with total hip replacement, blood cobalt and chromium(More)
BACKGROUND Metal skin clips are used in surgery. They may contain metals that might cause allergic reactions and delayed wound healing. METHODS The metal composition of 18 different surgical clamps was examined. The allergy status of 184 patients was determined by patch tests and was correlated with the clinical outcome of wound healing after application(More)
The activity of IMP dehydrogenase (EC, the key enzyme of de novo guanylate biosynthesis, was shown to be increased in tumor cells. Tiazofurin (TR), a potent and specific inhibitor of this enzyme, proved to be effective in the treatment of refractory granulocytic leukemia in blast crisis. We examined the effects of tiazofurin as a single agent and(More)
Increased ribonucleotide reductase (RR) activity has been linked with malignant transformation and tumor cell growth. Therefore, this enzyme is considered to be an excellent target for cancer chemotherapy. We have examined the effects of a newly patented RR inhibitor, trimidox (3,4,5-trihydroxybenzohydroxamidoxime). Trimidox inhibited the growth of human(More)
A tribologic assessment was performed on 22 metal-metal hip prostheses from a single manufacturer, following removal for early aseptic loosening after a mean service life of 32 months (range, 12-59 months). The mean linear wear rate was 7.6 microm/year (range, 2.9-12.8 microm/year). This was below the rates previously observed in other modern metal-metal(More)
The success of chemotherapy of colon tumours is currently limited. We have therefore used the human colon tumour cell line HT-29 to evaluate the cytotoxic effects of various drug combinations. Trimidox (3,4,5-trihydroxybenzamidoxime), a recently patented inhibitor of ribonucleotide reductase was combined with cytosinearabinoside (Ara-C) or(More)
  • 1